

Presentation to Analysts / Investors

Johnson Matthey Strategy Update – Building Our 3rd Century

29th January 2015





Cautionary Statement

This presentation contains forward looking statements that are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which Johnson Matthey operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results to differ materially from those currently anticipated.

Johnson Matthey



Johnson Matthey Strategy Update
Building Our 3rd Century

Robert MacLeod Chief Executive

Johnson Matthey



Programme

10.30	Introduction and Strategy Update Q&A after this session	Robert MacLeod
11.20	Fine Chemicals	John Fowler
11.40	Precious Metal Products Q&A after this session	Alan Myers
12.15	Lunch	
13.00	New Businesses	Nick Garner
13.25	Process Technologies	Geoff Otterman
13.40	Emission Control Technologies Q&A and coffee break after this session	John Walker
14.40	Technology	Liz Rowsell
15.00	Summary and final Q&A	Robert MacLeod
15.30	Coaches depart – Tour of Sonning Technology Centre	
17.45	Closing remarks	Robert MacLeod
18.00	Coach departs for Reading station / drinks reception and dinner	



Purpose of the Day

Update

on the group's long term strategy and priorities

Outline

key developments since January 2011

Explain

Divisional strategies and the fundamental role of technology in creating value

Highlight

how Johnson Matthey is positioned for superior long term growth





2011 – Our Strategy to Deliver Growth in Value









Continued core focus on leading edge catalysis

Maintain differentiation through technology

Strong position in pgms remains an intrinsic part of group

Primary focus is organic growth









Developing new opportunities underpinned by our core chemistry expertise

JM attributes

Manufacturing excellence

People and culture




JM has Delivered Strong, Consistent Performance

What w	re said in 2011	What we've done	Comment
uEPS	Growth at double digit rates with ROIC >20%	\checkmark	12.8% CAGR in uEPS, ROIC on track
EBITDA	Some growth in EBITDA margins (ex substrates)	lacksquare	Benefiting from manufacturing excellence and despite change in Anglo contracts
É	Increased R&D spend	lacksquare	Up 39%, maintained at 5% of sales
E	Invest in new businesses	lacksquare	New Businesses division established
\diamondsuit	Target net debt (incl. post tax pension deficit) / EBITDA 1.5 to 2.0 times	lacksquare	100p per share special dividend in August 2012
f M&A	Bolt-on M&A to accelerate organic growth	\checkmark	Key acquisitions in PT and NB
E	Average capex 1.2 to 1.3 times depreciation		Slightly higher (~1.4 times) – more investment required to support growth, especially ECT

In line with our expectations




Our 3C Strategy





JM Today – A Global Leader in Sustainable Technologies

Our **Vision** is to build our 3rd Century through value adding **sustainable technologies**





Our Purpose – What We Do

As a business we always aim to deliver what we promise.

We work together, applying our expertise in advanced materials and technology to innovate and improve solutions that:



are valued by our customers



optimise the use of natural resources



and enhance the quality of life for the people of the world, both for today and for the future




Sustainability Drivers Provide Superior Growth for JM

Global Drivers	Short to medium term	Longer term
Population Growth Urbanisation Increasing Wealth	JM well positioned in emerging markets • China represents 11% of sales	Growth from South America and other emerging markets
Natural Resource Constraints	Energy security – coal in China, gas in US Recycling of pgms – a strategic service	Alternative energy – biorenewables
Environmental Factors Climate Change Regulation	Continued tightening of emissions legislation • Vehicles • Industrial emissions • Fuel quality requirements	Electrification of powertrain Tighter regulation on pollutants in other industries (new business opportunities)
Health & Nutrition Ageing Population	Ongoing pressure on healthcare costs Increased use of generics	Enzymatic catalysis / more sustainable chemistry in pharma industry



Our Strategy for Superior Growth





Invest in Technology – How We Differentiate

- Strong set of technology skills
- Complex, 'difficult to do'
- Creates high barriers to entry
- Generates continuous stream of new products


But, what is most important is how you use them.....





Differentiation Through Technology

JM's skill lies in understanding both the chemistry and the applications



Chemistry has to be cutting edge

But we are more interested in, and good at, understanding how it can be used

That enables us to build multi million pound product businesses



Differentiation Through Technology - Complexity Matters

Operating at the frontiers of science enables lower risk, higher margin business models






JM has IP



Technical, reputational and legislative barriers to entry



Complex products that are difficult to emulate and are constantly improved

Sustains pricing / margins




Maximise value of technology through strong customer focus and reputation

We will continue to invest ~5% of sales p.a. in R&D to extend technology advantage



Build on Our Core Strengths

We will actively manage our portfolio to maintain focus



- Stay focused on markets which command high margins
- Exit areas that cease to benefit from our cutting edge expertise:
 - Gold and Silver refining
- ...or that do not fit with our business model
- Build and develop product offering in areas where synergies exist



Positioning for Growth

Improve efficiencies, maintain margins, grow sales



Health and Safety

Internal programmes to engage employees

Aspiration – zero accidents



Manufacturing Excellence

Drive for world class

Increase operational efficiencies

Maintain / grow margins



Sustainability

Sweet spot for JM

Resource efficiencies targeted to date

Future - develop new sustainable products



Best of Big and Small

Investment in core functions / systems

Upgrade business information systems

Enhance HR processes and talent management



Medium Term Targets and Priorities

	Targets	Priorities
ECT	High single digit CAGR in sales	 Continued development of service and products to maintain market position Drive operational efficiencies
PT	Mid to high single digit CAGR in sales	 Broaden offering Access strong share of opportunity from US shale gas and China coal
PMP	Mid single digit CAGR in sales	 Provides key services – further enhance reliability / efficiency of refineries Drive Manufacturing businesses for higher growth
FC	Mid to high single digit CAGR in sales	Invest in new products for medium term growthEnhance offering in Europe
NB	Invest £5m to £7m p.a. in organic growth £30m OP in Year 5	 Accelerate delivery of operating profit growth Develop new business pipeline

At stable margins



Investment and Capital Efficiency



Investment

- Average capital expenditure around 1.6 to 1.8 times depreciation
- Capital expenditure shifts from ECT to other divisions
- Investment in business systems



Capital efficiency remains embedded

- ROIC target >20%
- Net debt (incl. pension) / EBITDA
 between 1.5 to 2.0 times



Key Takeaways



Robust strategy in place
Strong market drivers



technologies
Using our expertise in advanced
materials and technology

Focus on sustainable



new product offerings R&D at 5% of sales p.a. to maintain competitive advantage

Build and develop




to accelerate growth
Ongoing £5-7m p.a.
>£100m p.a. OP by 2025



Operational Excellence
Drive operational efficiencies
and invest in internal systems
to maintain margins



Double digit growth in uEPS at >20% ROIC





Fine Chemicals Focus on Pharma for Future Growth

John Fowler

Division Director, Fine Chemicals



Fine Chemicals


Global supplier of APIs and other speciality chemical products and services for the pharmaceutical market


Fine Chemicals Today

- Leading positions for APIs in specific therapeutic areas
- Provider of development and manufacturing services to innovator pharmaceutical segment
- Expertise in catalysis and complex chemistry
- Strong return on sales

Positioning for the Future

- Geographic expansion
- Further expand position in high value niche drug segments and formulated products
- Investments in next generation drug development / manufacturing capability








Fine Chemicals – Business Background

Supply of API	Customers	Competitors	
 Market size ~\$1.5bn – niche segment of 'small' molecules API market #1 or #2 in majority of our markets including APIs for ADHD and palliative care 	TevaActavisMundipharma	MallinckrodtFrancopia	
Custom Services	Customers	Competitors	
 Market size ~\$30bn #3 provider of US development services 	Biogen IdecNektar	AMRICambridge Major	
Supply of Catalysts	Customers	Competitors	
Market Size ~\$0.5bn#2 position	• Syngenta	EvonikBASF	



Income Streams

- Generic API supply and profit sharing deals, catalysts
- Brand / Innovator API custom synthesis, catalyst service and sales
- Opportunistic licensing of novel API chemistry



Global Drivers Impacting Fine Chemicals

Global Drivers

Population Growth Urbanisation

Increasing Wealth

Health & Nutrition Ageing Population

Key Trends

Longer life expectancies

Economic development

Expanded access to healthcare

Drive to lower cost medicines

Sustainable chemistry

Fine Chemicals Growth Areas

Continued double digit growth in generics

Opportunity to capture more value and expand into new geographies

Relocation of API manufacturing from China / India

Increasing regulatory scrutiny provides opportunities

Enzyme capabilities and new reactor technologies

Development of efficient protein-based catalysts
Shift from batch to continuous flow production

Longer term opportunities in emerging markets

Pressure from WHO to make pain medication available



Fine Chemicals – A Pharma Focused Strategy

Growth ahead of the market



Increased penetration of niche generic APIs market



Accelerate **move up value chain** to formulated drug products



M&A to accelerate growth in product / services offering



Expand **custom services** capabilities in Europe and Asia



Increased technology differentiation



Sustained Differentiation Through Technology



- Expertise in complex organic chemistry
- Industry leading catalyst capabilities
- Purification science



- Access to most complex drug products
- Efficient, scalable production processes
- Consistent compliant manufacturing

...with Customer Focus

- Innovative business models with flexible value capture with balanced risk and reward
- IP generation and licensing
- Enabling the pharma industry to innovate and commercialise small molecule therapies

Customer Benefits and Value

Market access / product portfolio depth

Complex high value APIs

Speed to market



Vertical Integration – Moving Up the Value Chain

Key Divisional Growth Initiative

- Continue to expand beyond supply of controlled APIs
- Partner on drug product formulation, manufacturing and marketing
 - Enables shift from 'API sale' commercial model to higher value 'drug product profit share'
- Addressable JM market value increases significantly,
 *5 times

Example: Dofetilide

- Generic to Tikosyn®, antiarrhythmic agent, ~\$150m US brand
- Developed API using innovative chemistry for freedom to operate
- Partnered drug product manufacturing and marketing
- US FDA granted expedited review for the ANDA
- Potential 180 days of generic market exclusivity as 'first to file'

JM's ANDA Product Pipeline Evolution				
JM investment	~£5m p.a.	Accelerating co-development investment	~£10-15m p.a.	
# pending FDA approval	6 ———		>25	
# commercially launched	2 ———	→ >5 —	>20	
Target market – pipeline of current	~£80m p.a.		~£2.4bn p.a.	
brand drug sales	FY2015	FY2017	FY2019	

IMS Health, National Sales Perspectives, Oct 2014; listed trademarks are the property of their respective owners




Pharma Market Alignment Enhances Customer Focus and Growth

Johnson Matthey – Pharma Solutions **Global Development Technology and Custom Services Generics** and Manufacturing **Capability Network** West Deptford, US **Product / Process Development Catalyst and Chiral Technology Controlled Substance APIs** Conshohocken, US **Clinical Supplies Pgm-based APIs High Containment** Devens, US Edinburgh, UK **Commercial Manufacture ANDAs with Niche APIs Purification / Chromatography** Annan, UK Cambridge, UK **Solid Form Screening** Yantai, China Taloja, India Commercialisation **Clinical Development Generics**

29



Strategic Growth through Expanded Product-Service Offer Across Pharma Product Lifecycle and up the Value chain



Pharmaceutical Product Lifecycle



Fine Chemicals – Key Takeaways

Opportunities for double digit growth longer term



Strong market drivers and large potential opportunity



Leading API positions in existing markets



Growth from geographic expansion, migration across life cycle and up the value chain



Strategic focus on complex chemistry solutions for pharma industry



M&A could accelerate growth



Mid to high single digit growth medium term with stable margins



Precious Metal Products Investing for Growth

Alan Myers
Division Director, Precious Metal Products






Precious Metal Products (PMP)

High performance products for a range of industries; world leading pgm recycler

PMP Today

- Leading positions in key markets
- Some more mature businesses.
- Strong return on sales and ROIC
- Key developments
 - Change in the Anglo contracts
 - Disposal of gold and silver
 - Lower metal price sensitivity





Precious Metal Products – Drivers

Continued strong fundamentals for pgms

Global Drivers	Key Trends	•	Growth Drivers
Population Growth Urbanisation Increasing Wealth	Economic development		Continued demand for end of life autocatalyst recycling and pgm salts
Health & Nutrition Ageing Population	Longer life expectancies		Expanding use of minimally invasive surgery Continued growth in US demand for medical components and opportunities in Europe and Asia
Natural Resource Constraints	Focus on natural resource / energy efficiency		New opportunities to develop high performance products for higher growth industrial markets
Environmental Factors Climate Change Regulation	Drive for clean air	0 0 0 0 0 0 0 0 0 0 0	Sustained requirement for pgms in industrial applications



Precious Metal Products Strategy



Develop new products with more complex chemicals and lower pgm content



Drive continued efficiencies in pgm refineries and refining stream



Leverage core strengths in precious metals and materials chemistry



Bolt on acquisitions to expand capabilities



Ensure pgm supply to JM and customers



Drive growth in China



Differentiation Through Technology





Expertise in precious metal chemistry and its applications

- Alloy development
- Complex pgm chemicals
- Refinery process
- Silver paste

Example: Ignition Alloys

- Used in spark plugs market growth ~6% p.a.
- Expertise in chemistry of minor pgms and hot metal working
- Next generation alloys provide higher performance at lower cost
- Double digit growth for JM through value adding technology



Technology expertise
+ Precious metal management
+ Market insight
= Unique offering




Pgm Refining

Strategic service and growing demand

Market / business environment


- JM is #1 secondary refiner of pgm globally
 - Sales of £67m in 2013/14
- Long term partnerships with customers and suppliers
- Competitive market differentiated technology key to success
- Pgm demand increasing faster than primary supply secondary supply will bridge the gap



Future Growth Opportunities

- End of life autocatalysts
- Enhancements to refining process
- Plans to construct refinery in China







Noble Metals - Industrial

Steady performer, opportunities to accelerate growth

Market


- Wide range of end markets
- Key product areas
 - Nitric acid gauzes (#1 position)
 - Metallurgical including ignition products (#1 position)

Future Growth Opportunities

- Leverage technology and manufacturing expertise
 - Thrifted and lower cost alloys
 - More efficient production, new technology
 - New product development



Aim – Mid single digit growth in sales; opportunities for higher growth








Noble Metals – Medical Components

Strong position in a growing market

Market


- Pgm medical components
- Key products areas:
 - Cardiovascular electrophysiology
 - Other cardiovascular
 - Neurological
 - Cochlear
- JM growth in line with the market



Future Growth Opportunities

- Geographic expansion into Europe and Asia
 - Add dedicated development cells
- Bolt-on M&A







Advanced Glass Technologies

Opportunities for new products and new markets

Market

- Functional coatings for automotive glass market
 - Black obscuration enamels (market ~£100m)
 - Silver paste (market ~£60m)
- JM sales in 2013/14 £86m
- Strong market position
- Growth in line with light duty car market

Sales (ex pms) by Product Group 2013/14 £86m Functional - Other 25% Decorative Functional - Automotive

Future Growth Opportunities

- Opportunities for growth in China
- Apply current expertise to expand portfolio in technical glass materials
 - Medical applications glass market ~\$250m
 - Electronic applications glass market ~\$300m







Precious Metal Products — Key Takeaways Investing for future growth



Leverage core chemistry strengths and leading market positions



Investment in pgm refining in China



Accelerate growth through market expansion, new products and bolt-on acquisitions



Maintain strong ROIC while growing sales with at least stable margins




Drive further efficiencies in pgm refining



High single digit sales growth in Manufacturing businesses from 2016/17





New Businesses Generating the Next Growth Engines

Nick Garner


Division Director, New Businesses and Corporate Development

JM**⊗** Johnson Matthey



New Businesses

Creating growth engines of the future



New Businesses Strategy:

- Create new divisions with sales >£200m in ten years
- Look at areas adjacent to main operating business focus
- Build on core competences of JM but will involve development / acquisition of some key elements
- Further improve the generation and commercialisation of new products in JM
 - High tech, high margin with JM fit
 - Target developing markets with strong drivers
 - Portfolio of opportunities
 - M&A key to delivery



Developing a Portfolio of Opportunities

Ongoing investment of £5-7m p.a. in concept stage businesses

Concept stage



Indoor Air Purification



Cabin Air Purification



Low Carbon Vehicles



Atmosphere Control Technology

Commercialisation stage



Battery Technologies



Fuel Cells



Water Purification




- Rigorous investment appraisal
- Assessed against key milestones
- Must have capacity to deliver typical JM returns






Battery Technologies – The Opportunity

- Broad consensus that powertrain will diversify – volumes and timing uncertain
- Li-ion batteries for automotive applications expected to grow strongly
- Li-ion battery performance holding back mainstream commercialisation of fully electric vehicles



Source: Avicenne Energy, 2014 Note (1): Others is principally e-bikes, industrial and medical




(2) Adapted from Peter Lamp, BMW, AABC 2010



Battery Technologies – The Opportunity

- Li-ion materials market will be dominated by five major classes of chemistries over next ten years
- Market for cathode materials to grow strongly to 2025
- Next generation enhanced materials under development





Cathode Material Volumes. by Chemistry 350 300 250 12% 200 **CAGR** 150 100 50 0 2013 2025 Total 90k MT Total 350k MT ■ LCO ■ LMO ■ NMC ■ NCA ■ LFP

Source: Avicenne Energy, 2014




Battery Technologies – Why JM?


Strong fit with JM technology competences

Chemistry

- Focus on advanced, functional battery materials (initially Li-ion)
- Draw on JM strengths in functional materials
 - Promoters and dopants
 - Particle shape, morphology control
 - Surface coatings and treatments
 - Stabilisation and durability

Applications







Relationships with cell suppliers,
 OEMs, Tier 1s



Understanding of applications engineering = better product development



Battery Technologies — Strategy Building a competitive position...

Market focused research and R&D

Oct 2012



Axeon (£41m)

- System integration and applications knowledge
- Market insight

Oct 2014



A123
Manufacturing Assets
(£16m)

- LFP manufacturing in China
- Exclusive supply to A123

Feb / Mar 2015



Clariant Battery Materials Business (£49m)

- LFP manufacturing in North America
- R&D in Germany
- LFP IP
- Established customer base



Battery Technologies – Strategy

Building a competitive position... with a broad product portfolio

Battery Technologies today



- Credible supplier of cathode materials to cell industry
- Developing broader portfolio of cathode materials
 - In-license to accelerate in-house development
- Continued investment in R&D programmes
 - Next generation Li-ion and beyond



Battery Technologies roadmap



2015/16

- Sales >£100m
- Breakeven (excl. integration costs)
- Good growth in OP thereafter



2017/18

 Profitability established with only modest further investment



2019/20

- Sales ~£300m
- 20% ROIC

Scope to accelerate growth through delivery of new products and chemistry





Fuel Cells

Key element of vehicle powertrains

Opportunity

- Automotive market has started
 - CARB ZEV mandate
 - Japan Basic Energy Plan 2014 specifies move to hydrogen for fuel cell cars
- 2020: 10k-20k vehicles¹ p.a.
- 2025: 0.3-5.0m vehicles² p.a.


Why JM?

- Strong technology, good understanding of market
- Supported by JM's position as an automotive supplier

Strategy

- Convert existing OEM relationships into volume supply in next 2 to 3 years
- Position business for strong growth in automotive after 2020
- Continue R&D to meet 2025 MEA cost and performance targets

Projected Annual Light Duty Vehicle Sales by Technology Type



Market now more certain, supply chain still developing

¹OEM projections ² Jeffries "Fuel Cell Electric Vehicles: Benefits Without Compromise" 2014, Roland Berger Strategy Consultant "Fuel cells: A realistic alternative for zero emissions? " 2014







Water Purification

Opportunity

- Strong legislative drivers
 - Reduce contaminant levels
 - Increased water recycling
- Current existing markets >£500m in familiar areas – mining, oil and gas, chemicals

Why JM?

- Good fit with JM's chemistry and applications know how
- Advanced materials and processes
 - Adsorbents and catalysts
 - Tailored functionality
- Targets selective contaminants

Strategy

- Provide high technology, high margin products to treat challenging contaminants in niche markets
- Initial focus on Europe, Americas and China



Strong opportunities confirmed, significant progress dependent on M&A







Atmosphere Control Technologies (ACT)

Opportunity

- Strong global drivers
 - Efforts to minimise food waste and prolong produce life
 - Consumer demand to reduce use of chemical preservatives
 - Demand for convenience packaging
- \$1bn addressable market

Why JM?

- Complex ecosystem control
- Application of core competences
 - Coatings
 - Surface chemistry
 - Managing gases at ambient temperature

Strategy

- Develop atmosphere control technologies based on advanced functional materials
- Enhance conventional packaging and extend shelf life



Objective 1

Develop novel scavenging technologies through investment in R&D



Objective 2

Small scale M&A (up to £100m) to add technology and provide market access



Objective 3

Develop an extensive portfolio of solutions with global presence

Target – sales of £200m by 2025



New Businesses – Roadmap to 2025









- Sales ~£80m
- Operating loss ~£20m
- £150m investment in new business areas

- Division breakeven
- Battery Technologies profitable
- Fuel Cells breakeven
- ACT profitable after moderate M&A
- Water Purification modest M&A delivers profit; potential for more significant M&A

- £30m OP
- Total investment £250m
- ROIC > cost of capital
- >£100m OP no significant further investment
- Opportunity for higher OP with right M&A



New Businesses – Key Takeaways

On track with long term ambitions





To sustain superior growth for the group



Ongoing investment £5-7m p.a.

Maintain portfolio of opportunities



Target £200m sales p.a. businesses

Capable of meeting group returns



Expect breakeven for division in Year 3

Well positioned in battery technologies




M&A key to delivery

Rigorous financial criteria



Target **>£100m p.a.** operating profit from new businesses by 2025



Process Technologies Strategy for Growth

Geoff Otterman

Division Director, Process Technologies






Process Technologies (PT)

Manufactures speciality catalysts, licenses technology and provides services to the chemicals and oil and gas markets

PT Today

- Leading positions in targeted markets
- Strong growth opportunities supported by global drivers
- Creating value from combined strengths in catalyst and process technology
- Some short term headwinds...
 - Lower oil price limited direct impact on PT but creates uncertainty
 - Slow down in new projects and licences in China now expected to continue into 2015/16
- ...but long term fundamentals still in place
- Strategy to expand and broaden portfolio on track





Process Technologies - Drivers

Global Drivers

Population Growth Urbanisation Increasing

Wealth

Natural Resource Constraints

Environmental Factors
Climate Change Regulation

Key Trends

Economic development

Energy security

Restrictions on raw materials availability

Focus on natural resource / energy efficiency

Drive for clean air

Growth Drivers

Shale gas

New projects and growth based upon US shale gas and syngas based chemistry

Greater global demand for fuels

Especially cleaner fuels made from dirtier and less accessible feedstocks

Coal-based chemicals

China's drive for chemical and energy security

Demand for **asset performance and integrity** Increasing opportunities across our markets for high efficiency products






Shale Gas


Market Dynamics

- Low cost gas underpins new gas to chemicals investments
- Prospects for increased new plant activity
 - Progress on new ammonia plants
 - New methanol plants for China export market
- Gas to liquids (GTL) to monetise gas

Key Opportunities

- Strong growth from licensing and catalysts
 - Pipeline of new methanol and ammonia plants
- New GTL capacity in longer term
- JM has leading position in key syngas technologies
- Remains robust long term opportunity





Source: EIA






Global Demand for Fuels

Market Dynamics

- Clean fuels and trend to heavier sourer crudes underpins long term growth
- Growing demand for additives
- FCC capacity growth in Asia (fuels) and Middle East (chemicals) drives demand for additives
- New hydroprocessing capacity creates demand for new hydrogen plants

Key Opportunities

- Expect market fundamentals and business growth to remain strong
- Robust growth in key JM markets
 - Hydrogen catalysts 6% p.a.
 - Refinery additives 5-7% p.a.
- Opportunities to expand JM portfolio





Source: Hart Energy Research & Consulting






Coal-based Chemicals

Market Dynamics

- Energy demand / security drivers in China to meet needs of growing population
- Growing demand for key petrochemicals in China
- Coal to chemicals and SNG (substitute natural gas) technologies offer economic alternative to imports
- Balance between air quality issues and environmental concerns

Coal to SNG Capacity billion m³ 4 10 2011 2015E 2020E


Source: China Petroleum and Chemical Association and JM estimates



Source: Arthur D. Little

Key Opportunities

- Investment in new capacity for China requiring catalysts and processes
- JM portfolio of coal, gas and oil based technologies
- JM #1 position in SNG sector with nine projects licensed
- Portfolio strengthened with addition of new VCM and MEG technologies
- Long term view remains positive



Source: Arthur D. Little





Asset Performance and Integrity

Market Dynamics

- Capex pressures require
 - Greater value from more efficient processes and better catalyst technology
 - Use or reuse of older assets
- Financial and reputational risks of poor asset assurance

Key Opportunities

- Growth from innovative new products and services across PT's Chemicals and Oil and Gas businesses
 - High efficiency catalysts and reactors
 - Process changes and revamps
 - Smart technology for flow control, asset inspection and product assurance
- Good progress with introduction of new products and services





Process Technologies Strategy Progress since January 2014



Maintain leading positions in catalysts and process technologies for chemicals markets



Commercialisation of new technologies



Develop larger presence in oil and gas markets

- On track extending capabilities in catalysis
- Current market conditions may create M&A opportunities



Invest for growth

- R&D spend maintained at 5% of sales
- Short term capex revised in view of current conditions



Expand capabilities

- Working with key partners on new opportunities
- Exploring M&A in adjacent technologies

Broaden offering to deliver superior growth



Differentiation Through Technology

Unique combination of catalysts, know how and process technology



Catalysis and process understanding underpin technology leadership

Ability to integrate catalyst and process technology

- Creates value for JM and customer
- Develop technology for new markets
- Competitive edge



Deep understanding of customer operations adds value

Effective and safe technology transfer

- Customers integral to R&D process
- Partnerships accelerate commercialisation
- High project win rates

Example: Vinyl Chloride Monomer (VCM) in China

- New gold catalyst and process technology package
- Research done at JMTC
- Process IP developed with partner and acquired
- Replaces toxic mercury catalyst
- Expect new licences over next two years



R&D investment drives strong technology pipeline and new product delivery



Process Technologies – Key Takeaways

Well placed for long term growth







Expect short term slow down in some markets





Uniquely placed to create value through integrating catalyst and process technology



Continue to **invest to broaden portfolio** for
longer term growth



Medium term **mid to high single digit sales growth** on
average



Emission Control Technologies Motoring On and Driving Forward

John Walker

Executive Director, Emission Control Technologies







Emission Control Technologies (ECT)

Global leader in catalysts and technologies for light and heavy duty vehicles ECT Today

- Performing strongly on the back of long term investment in R&D and facilities
- Benefiting from:
 - Growth in vehicle markets
 - Tightening legislation requires new technology
 - Focus on operational excellence
 - Increasing capacity utilisation
- Stable positions in light and heavy duty sectors
- Air quality impact on public health remains major global focus







Global Drivers Support Growth in ECT

Global Drivers

Population Growth

Urbanisation

Increasing Wealth

Environmental Factors Climate Change Regulation

Key Trends

Public health

Continued focus on improving urban air quality

Economic development

Reduced environmental impact, more sustainable transport

Growth Drivers

Tightening legislation around the world

More stringent testing regimes

Increasing requirement for higher performance catalyst technologies

Emissions solutions for all global requirements

Sophisticated systems for developed markets
Tailored systems for developing markets
Increased car ownership in emerging markets drives catalyst volumes

Trend towards improved fuel efficiency (CO₂ reduction)

Mix of gasoline / diesel / hybrid systems to meet legislated targets and timeframes



Emission Control Technologies' Strategy





Invest in our people, products and technology

- R&D investment to maintain differentiation through technology
- High performance catalysts matched to local needs
- · Materials science and manufacturing

Customer focus

• A deep understanding of our markets and customers





Operational Excellence and Sustainability

- Optimum efficiency
- High quality products
- Supply chain

Create value

- Deliver superior growth
- Markets driven by global trends and regulation
- Rates above industry baselines



Technology – Accelerating Innovation, Maintaining Edge



 Full suite of products for global market requirements



- Global capabilities to support customer development and testing
- Increasing portfolio of tailored technology types
- Trend towards multifunctional catalysts
 - Customer demands, restricted space
- Design for manufacturing excellence
- Technologies for potential additional regulated emissions






Customer collaboration critical to successful innovation



Light Duty – Key Trends

Market Trends

- Strong volume growth in Asia, especially China
- European market below 2007 levels latent demand
- Engine size some reduction but very slow pace
- Powertrain developments
 - Diesel Europe remains main market, share expected to trend down only slightly
 - Low penetration for hybrids (5% by 2020)
 - Hybrids still need a catalyst
 - Catalyst value comparable to IC equivalent



Source: LMC Automotive

Legislative Trends

Europe

- Euro 6b for diesel now coming in adds ~20% in catalyst sales value for JM
- Euro 6c for some gasoline from 2017/18 doubles catalyst sales value for JM
 - Expect ~25% of gasoline vehicles initially and ~50% by 2021
- Real world driving emissions from 2017 will influence system selection

Asia

- China 5 nationwide in 2018 diesel filters
- Beijing 6
- India regulations delayed post 2017

North America

- Tier 3 on track for 2017 implementation
- GHG / fuel efficiency targets tightening to 2025
- PM standard may phase in by 2025 gasoline filters




Diesel – Key to Meeting CO₂ Targets

Diesel essential to the mix to meet tighter CO₂ targets


- Penalties for OEMs that miss fleet average targets
- UK today for cars meeting 2020 CO₂ standards, over 50% are diesel
- Difficult to radically change mix in current timeframe

Diesel continues to get cleaner


- Real world driving standards (anticipated 2017) –
 expect to have a major impact on emissions
 - System architecture likely to change more higher value components in mix for JM
- Technology exists today to meet even tighter standards
 - Similar emissions for diesel and gasoline







Source: Vehicle Certification Agency website





Strong Sales Growth Continues in Light Duty


Update since January 2013

- Market size forecast unchanged
 - \$6bn by 2015 and \$8bn by 2020
- European diesel remains the main value driver
- Asian car sales growth still adds further opportunity
- Higher value diesel market in Asia and US
- Still expect stable sector position



Light duty market continues to offer good growth potential

JM sales growth expected at 2 to 3% ahead of growth in global vehicle production




Source: LMC Automotive and JM estimates



Heavy Duty Diesel – Key Trends

Market Trends

- Current strong growth in Class 8 US truck sales expected to continue through 2015
- European truck production forecast to improve
 - Pent up demand following weak sales, ageing fleet
- Natural gas penetration in US slower than expected



Source: LMC Automotive; Johnson Matthey estimates for proportion regulated

Legislative Trends

Europe

- Euro VI now implemented
- Advanced discussions re. US GHG type legislation
- Non-road Stage V expected from 2019/20 will add value for JM

Asia

- China Euro IV nationwide from Jan 2015 drives volumes
- Beijing VI expected from 2018 Euro VI equivalent, adds filters
 - Potential for nationwide roll out post 2020
- India regulations delayed post 2017

North America

- GHG regulations tightening to 2020
- Discussions in California re. tighter NOx standards




HDD – A \$1.8bn Market by 2015, Growing to \$3.0bn by 2020

Update since January 2013

- 2015 market size estimate revised due to timing of non-road market
 - Stage V in Europe adds value from 2019
- Continued growth in China as legislation tightens
- Geographic expansion of tighter emissions standards





Source: LMC Automotive and JM estimates



Emission Control Technologies – Key Takeaways



Growth in all our markets



continues to deliver value



Create value from catalysts and manufacturing technology




JM continues to invest ahead of growth opportunities.




Strong positions in light duty and HDD to be maintained



High single digit sales growth on average





Johnson Matthey R&D


Dr Liz Rowsell


R&D Director, Johnson Matthey Technology Centre






Differentiation Through Technology








R&D to Deliver Future Growth





R&D Statistics

- Continued investment maintain at ~5% sales
- 1,400 employees 21% in JMTC
- JMTC sponsors work at over 30 universities in 9 countries
- A diverse community of nationalities, disciplines and age
- Highly collaborative approach
 - Strong links with customers and businesses
- Robust review processes
- High degree of know how, supported by strong IP portfolio





A Growing Network of Technology Centres



Savannah

- 4 employees
- Microporous materials



Billingham

- ~50 employees
- Process catalysis, engineering and scale up




Sonning Common

- ~250 employees
- Catalysis and materials, materials characterisation




Pretoria

- 6 employees
- Computer modelling



Singapore

- 7 employees 100 by 2020
- Functional materials





New Ventures



JMTC Singapore

- Vibrant international research community
 - Academic and applied
 - Strong in materials R&D
 - Diverse / collaborative environment / language
- Established collaboration with NTU (March 2014)
- Lease signed on ~1,900 m² of space in CleanTech 2
- Ambition 100 scientists and support staff by 2020



JM / Oxford University / Diamond Light Source Collaboration


- Creation of a state of the art materials characterisation facility – Harwell, UK
- JM and Oxford University to contribute cutting edge electron microscopes to Harwell's nanoprobe beamline
- Nanoprobe will deliver world's highest spatial X-ray resolution
- Allows characterisation of materials across scales
 - From catalyst active sites (atomic scale) to their location in the end product (micron scale)
- Greater understanding across scales to improve existing materials and design new ones




Optimising SCR Catalysts

Copper (Cu) zeolite NOx control catalysts for diesel engines

Zeolites – microporous crystalline solids with well defined pore architectures



Add Cu and zeolite materials become active for NOx reduction using ammonia (NH₃) as a reductant




Designed small pore Cu zeolites

- More thermally durable and selective for NOx reduction



Where is the Cu?

- Cu zeolites are examples of single site catalyst materials
 - Isolated Cu atoms represent the reaction site for the reaction of NOx and NH₃
 - Locating the Cu within the structure is key to understanding the superiority of the latest generation of catalysts



Use of probe molecules to bind to Cu and analyse using *in-situ* infra-red spectroscopy

Use of high resolution X-ray diffraction to identify Cu locations (at Diamond Light Source)

Possible Cu sites from modelling

Cu in Site II and IV



Gold Based VCM Catalyst





- JM developed an economically viable gold catalyst
 - Direct drop in for current mercury system
- Catalyst designed to be stable in highly acidic environments
- Superior yield and lifetime





 Currently commissioning catalyst production plant in Shanghai



The Application of Gold Chemistry

JM has long history of gold co-ordination chemistry in catalysis, inks, coatings and bio-materials






EPMA – Eggshell of Au complex on carbon

- Benign process was invented to coat surface of carbon support with stable gold complex at scale
- Surface location ('eggshell' allows low loading and high activity in highly acidic environment)
- Raman spectroscopy confirms the correct gold species against model system





Materials Characterisation


- JMTC Group Analytical provides world class characterisation of active materials
 - Provides insights into material properties
 - Combination of techniques
 - Enables improved performance and modification to prepare next generation materials


















Designing Improved Battery Materials

Design of functional materials by careful control of synthesis and processes




Particle Size

- Highly crystalline nano lithium titanate anode material prepared by flame spray pyrolysis
- Small particle size aids lithium ion movement



Coatings

- Coating lithium manganese oxide spinel with silica
- Stops metal leaching and prevents unwanted reactions




Dispersion

- Catalyst synthesis expertise
- Produces uniformly distributed multimetallic precursors for cathode materials




Beyond Li-ion Chemistry


- Li-air and Li-S batteries have potential to deliver greater energy densities
- Will rely on improved materials and chemistries
- External collaborations with internationally renowned academics to solve the technical challenges



 Li-air battery has potential to increase amount of energy that can be stored for a given weight



- Electrodes can be blocked by lithium peroxide
 - Particle size and shape important for cell lifetime



- JM is making and testing cathodes doped with pgms
 - Promotes oxygen dissociation
 - Stops undesired side reactions



Role of JMTC – Right Science at Right Time







In close collaboration with divisional teams



New product development
Supporting new business
development activities



Core science programmes

Extend and develop technologies
central to JM and applicable
across divisions



Collaboration with leading institutions
Keeps JM science
cutting edge




World class
High skilled scientists,
state of the art facilities



Tour of JMTC Sonning


Refining Research – Dr Emma Schofield
ECT – Dr Dave Thompsett
Battery Materials – Dr Sarah Ball and Dr James Cookson
Water Purification – Dr Alistair Kean and Dr Jonathan Sharman
New Applications – Dr Alison Wagland
Biomass Processing – Dr Mike Watson






JM Today – A Global Leader in Sustainable Technologies

Our **Vision** is to build our 3rd Century through value adding **sustainable technologies**






Our Strategy for Superior Growth





Differentiation Through Technology

JM's skill lies in understanding both the chemistry and the applications



Chemistry has to be cutting edge

But we are more interested in, and good at, understanding how it can be used

That enables us to build multi million pound product businesses



Key Takeaways



Robust strategy in place
Strong market drivers



Focus on sustainable technologies

Using our expertise in advanced materials and technology



Build and develop new product offerings

R&D at 5% of sales p.a. to maintain competitive advantage



Invest in new businesses to accelerate growth

Ongoing £5-7m p.a. >£100m p.a. OP by 2025



Operational Excellence

Drive operational efficiencies and invest in internal systems to maintain margins



Double digit growth in uEPS at >20% ROIC





JM Executive Board

Robert MacLeod

Chief Executive

Larry Pentz

Executive Director

Den Jones

Group Finance Director

John Walker

Executive Director
Emission Control Technologies



Presentation Team

Robert MacLeod

Chief Executive

John Fowler

Division Director Fine Chemicals

Alan Myers

Division Director
Precious Metal Products

Nick Garner

Division Director
New Businesses and
Corporate
Development

Geoff Otterman

Division Director Process Technologies

John Walker

Executive Director Emission Control Technologies

Dr Liz Rowsell

R&D Director Johnson Matthey Technology Centre



Other Senior Management

Emission Control Technologies

Chris Morgan
David Prest

Process Technologies

lain Martin
Joe Stevenson

Precious Metal Products

Mark Bedford

Fine Chemicals

Steve Barr Paul Evans

New Businesses

Jack Frost Martin Green

JMTC

Peter Bishop Mike Watson

Investor Relations

Katharine Burrow Sally Jones



Glossary

ACT ADHD ANDA API API gravity	Atmosphere Control Technologies Attention deficit and hyperactivity disorder Abbreviated New Drug Application Active pharmaceutical ingredient Measure of how heavy / light a petroleum liquid is compared to water	FC FCC FCEV GHG GTL HDD	Fine Chemicals Fluid catalytic cracking Fuel cell electric vehicle Greenhouse gas Gas to liquids Heavy duty diesel
Au	Gold	HEV	Hybrid electric vehicle
bbl	Oil barrel, a unit of volume	HR-TEM	High resolution transmission electron
BEV	Battery electric vehicle		microscopy
CAGR	Compound annual growth rate	IC	Internal combustion
CARB	California Air Resources Board	IP	Intellectual property
CCT	Catalysis and Chiral Technologies	JM	Johnson Matthey
CNG	Compressed natural gas	JMTC	Johnson Matthey Technology Centre
CO_2	Carbon dioxide	ktpa	Kilo tonnes per annum
CTČ	Coal to chemicals	LCO	Lithium cobalt oxide
Cu	Copper	LFP	Lithium iron phosphate
EBITDA	Earnings before interest, tax, depreciation	Li-air	Lithium-air, a type of battery cell chemistry
	and amortisation	Li-ion	Lithium-ion, a type of battery cell chemistry
ECT	Emission Control Technologies	Li-S	Lithium-sulfur, a type of battery cell chemistry
EDX	Energy dispersive x-ray, a characterisation	LMO	Lithium manganese oxide
	technique	LPG	Liquefied petroleum gas
EU	European Union		



Glossary

Pms

PT

Precious metals

Process Technologies

MEA MEG mmBtu mtpa NAFTA NB NCA NMC NMC	Membrane electrode assembly Mono ethylene glycol Million British Thermal Units Million tonnes per annum North American Free Trade Agreement New Businesses Lithium nickel cobalt aluminium oxide Lithium nickel manganese cobalt oxide Normal cubic metre (volume of gas under standard conditions of 0°C and 1atm pressure Nitrogen oxides	R&D ROIC ROW SEM SNG SS-NMR Syngas uEPS VCM WHO	Research and development Return on invested capital Rest of the world Scanning electron microscopy Substitute natural gas Solid state nuclear magnetic resonance spectroscopy A mixture of hydrogen and carbon oxides Underlying earnings per share Vinyl chloride monomer World Health Organization
	Nitrogen oxides	WHO	World Health Organization
OEM	Original equipment manufacturer	XPS	X-ray photoelectron spectroscopy
OP p.a.	Operating profit Per annum	XRD Zeolite	X-ray diffraction, a characterisation technique Microporous crystalline solid with well defined
Pgm	Platinum group metal		pore architecture
PHEV	Plug in hybrid electric vehicle		
PM PMP	Particulate matter Precious Metal Products		



180 Day Exclusivity

The period during which the first applicant to successfully file for a ANDA under Paragraph IV of the Wax-Hatchman Act is granted marketing exclusivity of a generic product.

ADHD – Attention Deficit Hyperactivity Disorder

A group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness.

ANDA – Abbreviated New Drug Application

Is an application for a US generic drug approval for an existing licensed medication or approved drug. The generic drug product needs to be comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use.

Antiarrhythmic drugs

Antiarrhythmic drugs are used to treat arrhythmia: a group of conditions used to describe abnormal heart rhythms.

API – Active Pharmaceutical Ingredient

A substance intended to have a pharmacological activity typically for the treatment, prevention or cure of a disease. Also known as Drug Substance.

Bioequivalence

Technical procedures and processes by which preparations of generics pharmaceuticals are tested and evaluated to ensure their performance will be equivalent to the original innovator product.

Biopharmaceutical or Biologics

Are medicinal products manufactured in or extracted from biological sources, for example vaccines, allergens, gene therapies, recombinant therapeutic proteins. See also Small Molecule.



Chirality / Chiral Technologies

The property of an organic chemical where it is different from its mirror image and cannot be superimposed upon it. This property is found throughout nature and is a critical aspect of pharmaceutical development. Derived from the Greek expression for 'handedness'.

Clinical Trials / Development

The formal process by which Investigation New Drugs are developed and tested, under the direction of regulatory authorities including the FDA and other regional organisations.

Continuous Flow / Continuous Processing

A manufacturing procedure by which reagents are continuously fed in to a flow reactor, forming products which are then discharged also on a continuous basis. Often resulting in higher yields, more profitable processes with lower costs for operation, equipment, and investment.

Controlled Substances / Drugs

A controlled substance is generally a drug or chemical whose manufacture, possession, or use is regulated by a government, typically because they have the potential for abuse or dependence.

Crystalline Form

Physical characteristics of crystalline Active Pharmaceutical Ingredients, which will determine aspects of its performance such as stability, compatibility, dissolutions rate etc.

Dossier (Pharmaceutical)

Formal documentation and submissions made to regulatory agencies required to be approved for marketing authorisation of pharmaceutical products.



Drug Product

A finished dosage form, for example, tablet, capsule, solution, etc., that contains one or more APIs. Also known as Formulated Product.

Drug Substance

A substance intended to have a pharmacological activity typically for the treatment, prevention or cure of a disease. Also known as API.

EMEA – European Medicines Agency

European Union agency responsible for the protection of public and animal health through the scientific evaluation and supervision of medicines.

Enzymes

Enzymes are biological molecules (proteins) that act as catalysts and can be used to enable chemical reactions with high rates and levels of selectivity catalysts.

FDA Approval

Following the FDA's Drug Review Process which includes safety, efficacy, potential side effects and so forth, the Agency can approve drug products for sales and marketing.

FDA - Food and Drug Administration

The Food and Drug Administration (FDA or USFDA) is a federal agency of the United States Department of Health and Human Services.

First to File

Relates to the Wax-Hatchman Act (1984) regarding the process by which generics drug manufacturers submit ANDA filing for FDA approval. More specifically under Paragraph IV, the first company to successfully file an ANDA is granted a 180 days marketing exclusivity for the generic product.



Formulated Product

A finished dosage form, for example, tablet, capsule, solution, etc., that contains one or more APIs. Also known as Drug Product.

Generic Drug

A drug produced and marketed after a proprietary drug goes off patent. Note they must still meet the standards of GMP set out by pharmaceutical regulatory bodies.

GMP – Good Manufacturing Practice

Regulations and controlled set out by the FDA, EMEA and other regulatory bodies that set out the guidelines for pharmaceutical manufacture.

High Containment

A specific manufacturing requirement for specific types of API that have high potency (are active in extremely small quantities).

IMS Health

IMS Health is a leading provider of information and services to the healthcare industry.

Innovator

Pharmaceutical companies predominantly engaged in the research, development, clinical studies and commercialisation of novel materials to be used as therapeutic agents. See also Generic Drug.

Palliative Care

When there is no cure for an illness, palliative care tries to make the end of a person's life as comfortable as possible. This is done by attempting to relieve pain and other distressing symptoms.



NDA - New Drug Application

Is the vehicle in the United States through which drug sponsors formally propose that the Food and Drug Administration (FDA) approve a new pharmaceutical for sale and marketing.

PGM-Based APIs

Active Pharmaceutical ingredients which contain a platinum group metal as part of the chemical structure, commonly platinum.

Registered Intermediates

Registered Intermediates are isolated intermediates that are produced under GMP regulation from registered starting materials in the process to make APIs.

Solid Form Screening

Processes by which Crystalline Form and other physiochemical properties are studied and investigated to optimise the performance of Active Pharmaceutical Ingredients.

Small Molecule

Conventional therapeutic agents manufactured using conventional chemical synthesis, see also Biologics.

Starting Materials

Defined by the FDA and other regulatory agencies as the chemical starting point from which GMP regulations are introduced into the synthesis of APIs.

